Join the club for FREE to access the whole archive and other member benefits.

Eric Morgen

COO and Co-founder at BioAge Labs

Eric oversees BIOAGE’s clinical and computational efforts to bring new therapeutics to the clinic that target fundamental mechanisms of aging. Eric was previously an assistant professor at the University of Toronto, where his research focused on biomarker discovery and characterization in high-dimensional datasets from human cohorts. He completed an HBSc in artificial intelligence, MD, clinical training in pathology, and a research fellowship in computational biology and molecular epidemiology at the University of Toronto, where he held a Canada Graduate Scholarship from the CIHR, and was subsequently a CIHR research fellow. He has published over 15 papers in the areas of molecular biomarker discovery, pharmacogenomics, aging, and diagnostic medicine. Eric is a licentiate of the Medical Council of Canada, a fellow of the Royal College of Physicians and Surgeons of Canada, holds a specialty designation in pathology, and previously practiced medicine at Mount Sinai Hospital in Toronto.

Visit website: https://bioagelabs.com/team/#eric

 eric-morgen-63a6012a

 eric_k_morgen

See also: Company BIOAGE - Developing a broad pipeline of therapies to extend human healthspan and lifespan

Details last updated 28-Dec-2022

Eric Morgen is also referenced in the following:

ARDD 2023 - 10th Aging Research & Drug Discovery Meeting

28-Aug-2023 to 01-Sep-2023

Event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen

BIOAGE

Developing a broad pipeline of therapies to extend human healthspan and lifespan

Global Healthspan Summit 2023

29-Nov-2023 to 30-Nov-2023

Longevity summit organised by Hevolution Foundation (Riyadh,Saudi Arabia)

Eric Morgen News

Lifespan.io summarises the proceedings of the Buck Institute's Longevity Summit

Lifespan.io summarises the proceedings of the Buck Institute's Longevity Summit

Lifespan.io (LEAF) - 20-Jan-2023

Another reminder of the amount of research, with multiple approaches, about to go into clinical trials